Literature DB >> 10992362

Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.

F Millán-Rodríguez1, G Chéchile-Toniolo, J Salvador-Bayarri, J Huguet-Pérez, J Vicente-Rodríguez.   

Abstract

PURPOSE: We evaluated the prognostic factors of primary superficial bladder cancer that may predict a metachronous upper urinary tract tumor. We also determined whether the incidence of upper urinary tract disease varies according to risk group based on primary superficial bladder tumor classification.
MATERIALS AND METHODS: We studied disease evolution in a cohort of 1,529 patients with a primary superficial bladder tumor. To determine the prognostic factors of upper urinary tract cancer we performed multivariate analysis using Cox regression. Independent variables were grade, T stage, multiplicity, tumor size, carcinoma in situ association, previous or synchronous upper urinary tract tumor and intravesical instillation. We also performed the chi-square test and Kaplan-Meier survival analysis to assess the variable incidence of upper urinary tract tumors according to primary superficial bladder tumor risk group classification.
RESULTS: The incidence of upper urinary tract cancer was 2.6%. The only factor prognostic for an upper urinary tract tumor was multiplicity (relative risk 2.7, 95% confidence interval [CI] 1.06 to 6.84). All patients with an upper urinary tract tumor had a previously recurrent primary superficial bladder tumor. In the low, intermediate and high risk groups the incidence of upper urinary tract cancer was 0.6% (relative risk 1), 1.8% (relative risk 3.1, 95% CI 0.4 to 23.9) and 4.1% (relative risk 8.3, 95% CI 1.1 to 61.6), respectively (chi-square and log rank tests p = 0.007 and p <0.05, respectively).
CONCLUSIONS: A higher risk of upper urinary tract cancer must be expected in cases of multiple primary superficial bladder tumors. This finding supports the multicentricity theory of transitional cell carcinoma. Primary superficial bladder tumor classification by risk group is also useful for predicting the various risks of metachronous upper urinary tract cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10992362

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

Review 1.  [Diagnostic procedure for bladder cancer. Standards and current developments].

Authors:  A Karl; S Tritschler; D Zaak; D Tilki; C Stief; M Burger
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

2.  Bladder cancer: is contrast-enhanced CT necessary for following up NMIBC?

Authors:  Mesut Remzi; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2013-08-06       Impact factor: 14.432

3.  [Aftercare of non-muscle invasive bladder cancer].

Authors:  G B Schulz; B Schlenker; C G Stief
Journal:  Urologe A       Date:  2019-08       Impact factor: 0.639

4.  Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.

Authors:  Dong Fang; Lei Zhang; Xuesong Li; Gengyan Xiong; Xiaopeng Chen; Wenke Han; Zhisong He; Liqun Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-28       Impact factor: 4.553

Review 5.  [Short version of the German S3 guideline for bladder cancer].

Authors:  M Retz; J E Gschwend; P Maisch
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

6.  Best practice in the treatment of nonmuscle invasive bladder cancer.

Authors:  Anastasios Anastasiadis; Theo M de Reijke
Journal:  Ther Adv Urol       Date:  2012-02

7.  Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study.

Authors:  Philipp Nuhn; Giacomo Novara; Christian Seitz; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Hans-Martin Fritsche; Stefan Tritschler; Juan I Martínez-Salamanca; Vincenzo Ficarra; Pierre I Karakiewicz; Guido Mazzoleni; Shahrokh F Shariat; Patrick J Bastian
Journal:  World J Urol       Date:  2014-07-22       Impact factor: 4.226

8.  Saudi Oncology Society clinical management guidelines for urinary bladder cancer.

Authors:  Khaled Al Othman; Shouki Bazarbashi; Khalid Balaraj; Mohamed Al Otaibi; Baher Kamal; Ibraheem Al Oraifi; Eyad Al Saeed; Khalid Al Gamdi; Ali Jubran; Ahmad Salah; Jalal Al Shareef; Jamal Zekri
Journal:  Urol Ann       Date:  2011-03

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.